Teva Announces U.S. Approval of AJOVY™ (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults Guest UserSeptember 26, 2018 Facebook0 Twitter LinkedIn0 0 Likes